Awarded
El objeto del contrato viene determinado por el suministro del principio activo denominado "TRASTUZUMABDERUXTECAN 100MG VIAL PERFUSION IV".
Track this recordFree account — get alerted when a contract here runs out.
- Winners
- DAIICHI SANKYO ESPAÑA S.A.
- Contract value
- €817,703
- Bids received
- 1
- Published
- 7 Mar 2025
- Awarded
- 3 Mar 2025
- Contract start
- 3 Mar 2025
- Contract end
- 4 Mar 2026estimated